FDA Accepts Supplement for NUZYRA (Omadacycline) by Paratek Pharmaceuticals
The FDA has accepted a supplemental NDA for NUZYRA, an antibiotic containing omadacycline tosylate, submitted by Paratek Pharmaceuticals.
Company
Pharmaceutical intelligence for Paratek Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.